Oncolytics Biotech
在场
Oncolytics Biotech 是一家在股票代码 ONC (CA) 下上市的公司。
高管
查看带有其 12 名主要高管的组织结构图
Oncolytics Biotech 搜索最多的简介
高管在Oncolytics Biotech变化
- Wayne Pisano 曾任 Chairman of the Board, 现升职为 Interim Chief Executive Officer (新闻发布的2024六月25号).
- Matthew Coffey, who was Director, President and Chief Executive Officer, has left for medical reason. We wish Matthew a prompt recovery (新闻发布的2024六月25号).
创建提醒
跟踪 Oncolytics Biotech 的高管变动
生物技术
Oncolytics Biotech 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
Oncolytics Biotech 的最新新闻稿
- Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights | Oncolytics Biotech Inc.
- Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights | Oncolytics Biotech Inc.
- Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path | Oncolytics Biotech Inc.
- Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study | Oncolytics Biotech Inc.
- Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September | Oncolytics Biotech Inc.
- Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights | Oncolytics Biotech Inc.
- Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights | Oncolytics Biotech Inc.
- Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference | Oncolytics Biotech Inc.
- Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer | Oncolytics Biotech Inc.
- Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program | Oncolytics Biotech Inc.
- View more press releases Close
通过电子邮件
